presence of HCV infection should be more significant to avoid or decrease the risk of teratogenic consequences and neonatal thyroid dysfunction. Hopefully, several pharmacogenomics methods will be used to recognize the activity of maternal thyroid gland during the gestation previous to the initiation of HCV treatments. Additional work is vital to determine the developmental (the metabolic pathways), molecular and biochemical disruption mechanisms of maternal HCV infection and its treatment during the fetal and neonatal development. Clinical examinations are still essential to understand the associations between the chronic HCV infection and the prevalence of maternofetal autoimmune thyroid disorders and thyroid cancer. As well, several studies are required to discover novel drugs for HCV treatment and new therapeutic approaches to improve the maternofetal and neonatal health consequences, and to decrease the morbidity and mortality in fetuses, neonates or child.
